Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01213160
Other study ID # D2610C00002
Secondary ID
Status Completed
Phase Phase 1
First received September 30, 2010
Last updated June 28, 2016
Start date November 2010
Est. completion date June 2013

Study information

Verified date June 2016
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and WelfareJapan: Pharmaceuticals and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to explore the safety and tolerability of AZD4547 in Japanese patients with advanced solid malignancies.


Description:

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients with Advanced Solid Malignancies.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 25 Years to 150 Years
Eligibility Inclusion Criteria:

- Japanese patients with advanced solid malignancies Over 25 years old Relatively good overall health other than cancer

Exclusion Criteria:

- Poor bone marrow function (not producing enough blood cells). Poor liver or kidney function. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the IP or previous significant bowel resection.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
AZD4547
film coated tablet, PO, twice daily

Locations

Country Name City State
Japan Research Site Chuo-ku
Japan Research Site Nagoya-shi
Japan Research Site Sapporo-shi

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of adverse events (based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)general examination General examination prior to IP administration in treatment cycles Yes
Primary Assessment of adverse events (based on CTCAE version 4.0)general examination General examination on day 1 in cycle 0 Yes
Primary Assessment of adverse events (based on CTCAE version 4.0)general examination General examination day 21 in cycle 1. Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), laboratory values Laboratory assessment prior to IP administration in all treatment cycles Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), laboratory values Laboratory assessment on day 1 in cycle 0 Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), laboratory values Laboratory assessment day 1 cycle 1. Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), laboratory values Laboratory assessment day 8 cycle 1. Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), laboratory values Laboratory assessment day 15 cycle 1. Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), laboratory values Laboratory assessment day 21 cycle 1. Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements Vital sign measurements prior to IP administration in all treatment cycles Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements Vital sign measurements day 1 in cycle 0 Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements Vital sign measurements day 2 in cycle 0 Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements Vital sign measurements day 8 in cycle 1. Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), vital sign measurements Vital sign measurements day 21 in cycle 1. Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), left ventricular ejection fraction (LVEF) LVEF prior to study administration Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), LVEF LVEF on day 21 in cycle 1. Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), eye examination Eye examination prior to study administration Yes
Primary Assessment of adverse events (based on CTCAE version 4.0), eye examination Eye examination on day 21 in cycle 1. Yes
Secondary Define the maximum tolerated dose (MTD) if possible or biological effective dose. Up to 3 weeks Yes
Secondary To explore the pharmacokinetics (PK) of AZD4547and metabolite in Japanese patients with advanced solid malignancies when given AZD4547 orally. Schedule of PK assessment 1. AZD4547; blood Cycle0-day1 -day21; 27 point 2. AZD4547 metabolite; blood Cycle1-day21; 1 poin 3. AZD4547; urine Cycle1-day21; 1 point Yes
Secondary To obtain a preliminary assessment of the anti-tumour effect of AZD4547 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) criteria v1.1. Schedule of CT/MRI etc-screeing-cycle1 day21-every 6 weeks-the end of treatment No
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients

External Links